{"url_path":"/sec/clrb/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-060678-index.html","accession_number":"0001104659-26-060678","cik":"0001279704","ticker":"CLRB","issuer_name":"Cellectar Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-060678-index.html","primary_entity_key":"0001279704","primary_entity_name":"Cellectar Biosciences, Inc."},"word_count":1225,"has_tables":true,"body_markdown":"Cellectar Biosciences, Inc._March 31, 2026\n\nDE0001279704--12-312026Q1falseCellectar Biosciences, Inc.5653946274787446http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants111.11111.11111.11111.11424012942401290.100.0330.0330.033http://fasb.org/us-gaap/2025#CostsAndExpenses13206026132060260001279704srt:MinimumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001279704clrb:September2023WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001279704clrb:September2023WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001279704clrb:September2023WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001279704clrb:September2023WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-03-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-03-310001279704clrb:July2024WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001279704clrb:July2024WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001279704clrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001279704clrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-03-310001279704srt:MinimumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001279704srt:MinimumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001279704srt:MinimumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001279704srt:MinimumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001279704srt:MinimumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001279704srt:MinimumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001279704srt:MaximumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001279704srt:MaximumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001279704srt:MaximumMemberclrb:September2023WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001279704srt:MaximumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001279704srt:MaximumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001279704srt:MaximumMemberclrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001279704clrb:September2023WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-12-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-12-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-12-310001279704clrb:July2024WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-12-310001279704clrb:October2022WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-10-3100012797042025-01-012025-12-310001279704us-gaap:SeriesDPreferredStockMember2026-03-310001279704clrb:SeriesDConvertiblePreferredStockMember2026-03-310001279704us-gaap:SeriesDPreferredStockMember2025-12-310001279704clrb:SeriesDConvertiblePreferredStockMember2025-12-310001279704us-gaap:SeriesDPreferredStockMember2025-03-310001279704us-gaap:SeriesDPreferredStockMember2024-12-310001279704us-gaap:SubsequentEventMemberclrb:RegisteredDirectOfferingMember2026-05-052026-05-050001279704clrb:SeriesE1PreferredStockMemberclrb:September2023PrivatePlacementMember2023-09-082023-09-0800012797042025-06-242025-06-240001279704srt:MinimumMember2025-06-232025-06-230001279704srt:MaximumMember2025-06-232025-06-2300012797042025-06-182025-06-180001279704us-gaap:RetainedEarningsMember2026-03-310001279704us-gaap:AdditionalPaidInCapitalMember2026-03-310001279704us-gaap:RetainedEarningsMember2025-12-310001279704us-gaap:AdditionalPaidInCapitalMember2025-12-310001279704us-gaap:RetainedEarningsMember2025-03-310001279704us-gaap:AdditionalPaidInCapitalMember2025-03-310001279704us-gaap:RetainedEarningsMember2024-12-310001279704us-gaap:AdditionalPaidInCapitalMember2024-12-310001279704us-gaap:PreferredStockMember2026-03-310001279704us-gaap:CommonStockMember2026-03-310001279704us-gaap:PreferredStockMember2025-12-310001279704us-gaap:CommonStockMember2025-12-310001279704us-gaap:PreferredStockMember2025-03-310001279704us-gaap:CommonStockMember2025-03-310001279704us-gaap:PreferredStockMember2024-12-310001279704us-gaap:CommonStockMember2024-12-310001279704srt:MinimumMember2026-01-012026-03-310001279704srt:MaximumMember2026-01-012026-03-310001279704srt:MinimumMember2025-01-012025-03-310001279704srt:MaximumMember2025-01-012025-03-310001279704us-gaap:ResearchAndDevelopmentExpenseMemberclrb:EmployeeAndDirectorStockOptionMember2026-01-012026-03-310001279704us-gaap:GeneralAndAdministrativeExpenseMemberclrb:EmployeeAndDirectorStockOptionMember2026-01-012026-03-310001279704clrb:EmployeeAndDirectorStockOptionMember2026-01-012026-03-310001279704us-gaap:ResearchAndDevelopmentExpenseMemberclrb:EmployeeAndDirectorStockOptionMember2025-01-012025-03-310001279704us-gaap:GeneralAndAdministrativeExpenseMemberclrb:EmployeeAndDirectorStockOptionMember2025-01-012025-03-310001279704clrb:EmployeeAndDirectorStockOptionMember2025-01-012025-03-310001279704us-gaap:LeaseholdImprovementsMember2026-03-310001279704srt:MinimumMember2026-03-310001279704srt:MaximumMember2026-03-310001279704clrb:PublicOfferingMember2025-07-022025-07-020001279704clrb:SeriesE2PreferredStockMemberclrb:September2023PrivatePlacementMember2026-03-310001279704clrb:SeriesE2PreferredStockMember2026-03-310001279704clrb:SeriesE2PreferredStockMember2025-12-310001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMemberclrb:SeriesE4PreferredStockMember2024-07-210001279704us-gaap:RetainedEarningsMember2025-01-012025-03-310001279704clrb:CancerTreatmentResearchAwardThroughNationalCancerInstituteMember2022-09-012022-09-300001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2026-03-310001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-12-310001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-03-310001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-12-310001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001279704us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-03-310001279704clrb:September2023WarrantsMember2026-01-012026-03-310001279704clrb:July2024WarrantsMember2026-01-012026-03-310001279704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001279704clrb:September2023WarrantsMember2026-03-310001279704clrb:October2022WarrantsMember2026-03-310001279704clrb:July2024WarrantsMember2026-03-310001279704clrb:September2023WarrantsMember2025-12-310001279704clrb:October2022WarrantsMember2025-12-310001279704clrb:July2024WarrantsMember2025-12-310001279704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001279704us-gaap:SubsequentEventMemberclrb:RegisteredDirectOfferingMember2026-05-050001279704clrb:TrancheCWarrantsMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-05-050001279704clrb:TrancheBWarrantsMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-05-050001279704clrb:TrancheaWarrantsMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-05-050001279704clrb:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-05-050001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMember2024-07-310001279704clrb:TwoThousandTwentyThreeTranchePreferredWarrantsMemberclrb:SeriesE3PreferredStockMemberclrb:September2023PrivatePlacementMember2023-09-080001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMemberclrb:SeriesE4PreferredStockMemberclrb:September2023PrivatePlacementMember2023-09-080001279704clrb:TwoThousandTwentyTwoCommonWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFourTrancheCWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFourTrancheBWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFourTrancheaWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFiveRepresentativeWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFiveOctoberSeriesTwoCommonWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFiveOctoberSeriesOneCommonWarrantsMember2026-03-310001279704clrb:TwoThousandTwentyFiveJulyCommonWarrantsMember2026-03-310001279704clrb:October2022PublicOfferingAndPrivatePlacementMember2026-03-310001279704clrb:CommonStockWarrantMemberclrb:PublicOfferingMember2025-07-020001279704clrb:TwoThousandTwentyFiveRepresentativeWarrantsMember2025-07-020001279704clrb:ExistingWarrantsMember2025-06-0600012797042025-03-3100012797042024-12-310001279704us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001279704us-gaap:FairValueMeasurementsRecurringMember2026-03-310001279704us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001279704us-gaap:FairValueMeasurementsRecurringMember2025-03-3100012797042024-05-0600012797042022-12-300001279704us-gaap:WarrantMember2026-01-012026-03-310001279704us-gaap:StockOptionMember2026-01-012026-03-310001279704clrb:PreferredSharesAsConvertibleIntoCommonStockMember2026-01-012026-03-310001279704us-gaap:WarrantMember2025-01-012025-03-310001279704us-gaap:StockOptionMember2025-01-012025-03-310001279704clrb:PreferredSharesAsConvertibleIntoCommonStockMember2025-01-012025-03-310001279704us-gaap:SeriesDPreferredStockMember2026-01-012026-03-310001279704us-gaap:RetainedEarningsMember2026-01-012026-03-310001279704us-gaap:PreferredStockMember2026-01-012026-03-310001279704us-gaap:CommonStockMember2026-01-012026-03-310001279704us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001279704us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100012797042025-12-3100012797042026-05-1200012797042025-06-062025-06-060001279704clrb:TwoThousandTwentyTwoCommonWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFourTrancheCWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFourTrancheBWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFourTrancheaWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFiveRepresentativeWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFiveOctoberSeriesTwoCommonWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFiveOctoberSeriesOneCommonWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFiveJulyCommonWarrantsMember2026-01-012026-03-310001279704clrb:TwoThousandTwentyFourTrancheCWarrantsMember2024-07-212024-07-210001279704us-gaap:SubsequentEventMember2026-05-050001279704clrb:CancerTreatmentResearchAwardThroughNationalCancerInstituteMember2026-01-012026-03-310001279704clrb:CancerTreatmentResearchAwardThroughNationalCancerInstituteMember2025-01-012025-03-310001279704clrb:TwoThousandTwentyFiveOctoberWarrantsMember2025-10-072025-10-070001279704us-gaap:CommonClassBMemberclrb:PublicOfferingMember2025-07-0200012797042025-10-072025-10-070001279704clrb:PrefundedWarrantMemberus-gaap:CommonClassBMemberclrb:PublicOfferingMember2025-07-020001279704clrb:CommonStockWarrantMemberus-gaap:CommonClassBMemberclrb:PublicOfferingMember2025-07-020001279704clrb:CommonStockWarrantMemberus-gaap:CommonClassAMemberclrb:PublicOfferingMember2025-07-020001279704us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2026-05-052026-05-050001279704us-gaap:CommonClassBMemberclrb:PublicOfferingMember2025-07-022025-07-020001279704us-gaap:CommonClassAMemberus-gaap:OverAllotmentOptionMember2025-07-022025-07-020001279704us-gaap:CommonClassAMemberclrb:PublicOfferingMember2025-07-022025-07-020001279704us-gaap:CommonClassAMemberclrb:PublicOfferingMember2025-07-020001279704clrb:TwoThousandTwentyFourTrancheBWarrantsMember2024-07-210001279704clrb:TwoThousandTwentyFourTrancheCWarrantsMember2024-07-210001279704clrb:TwoThousandTwentyFourTrancheaWarrantsMember2024-07-2100012797042026-03-3100012797042024-05-062024-05-060001279704clrb:SingleReportableSegmentMember2026-01-012026-03-310001279704clrb:SingleReportableSegmentMember2025-01-012025-03-310001279704clrb:TwoThousandTwentyThreeTrancheBPreferredWarrantsMemberclrb:SeriesE4PreferredStockMember2024-07-212024-07-210001279704clrb:ExistingWarrantsMember2025-06-062025-06-0600012797042026-01-012026-03-3100012797042025-01-012025-03-3100012797042025-10-070001279704clrb:TwoThousandTwentyFiveOctoberWarrantsMember2025-10-07iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesclrb:Dclrb:itemxbrli:pureutr:sqftclrb:segmentclrb:Y\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n**U.S. SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n[mark one]\n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended: March 31, 2026\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ______________ to ______________\n\n**Commission File Number****1-36598**\n\n​\n\n**CELLECTAR BIOSCIENCES, INC.**\n\n(*Exact name of registrant as specified in its charter*)\n\n​\n\n​\n\n**DELAWARE**\n\n**04-3321804**\n\n(*State or other jurisdiction of*\n\n(*IRS Employer*\n\n*incorporation or organization*)\n\n*Identification No.*)\n\n​\n\n**100 Campus Drive**\n\n**Florham Park****,****New Jersey********07932**\n\n(*Address of principal executive offices, including zip code*)\n\n**(****608****)****441-8120**\n\n(*Registrant’s telephone number, including area code*)\n\n(*Former name, former address and former fiscal year, if changed since last report)*\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n​\n\n**Title of each class**\n\n  ​ ​ ​\n\n**Trading Symbol(s)**\n\n  ​ ​ ​\n\n**Name of each exchange on which registered**\n\nCommon stock, par value $0.00001\n\n​\n\nCLRB\n\n​\n\nNASDAQ Capital Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nNumber of shares outstanding of the issuer’s common stock as of the latest practicable date: 7,991,812 shares of common stock, $0.00001 par value per share, as of May 12, 2026.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nCELLECTAR BIOSCIENCES, INC.\n\nFORM 10-Q INDEX\n\n​\n\n \n\n[Forward-Looking Statements](#FORWARDLOOKINGSTATEMENTS_613028)\n\n3\n\n \n\n \n\n \n\n[**PART I. FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_278295)\n\n5\n\n \n\n \n\n \n\n[Item 1.](#Item1FinancialStatements_485987)\n\n[Financial Statements](#Item1FinancialStatements_485987)\n\n5\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysisofF)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n22\n\n[Item 4.](#Item4ControlsandProcedures_198630)\n\n[Controls and Procedures](#Item4ControlsandProcedures_198630)\n\n32\n\n \n\n \n\n \n\n[**PART II. OTHER INFORMATION**](#PARTIIOTHERINFORMATION_767766)\n\n34\n\n \n\n \n\n \n\n[Item 1.](#Item1LegalProceedings_929435)\n\n[Legal Proceedings](#Item1LegalProceedings_929435)\n\n34\n\n[Item 1A.](#Item1ARiskFactors_374157)\n\n[Risk Factors](#Item1ARiskFactors_374157)\n\n34\n\n[Item 6.](#Item6Exhibits_813179)\n\n[Exhibits](#Item6Exhibits_813179)\n\n36\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\n**FORWARD-LOOKING STATEMENTS**\n\nThis quarterly report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”, “Cellectar”, “we”, “us”, “our”) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include:\n\n●our current views with respect to our business strategy, business plan and research and development activities;\n\n●the progress of our product development programs, including clinical testing and the timing of commencement and results thereof;\n\n●statements regarding execution of our regulatory strategy, including related to our potential initiation of a Phase 3 trial of iopofosine I 131 (also known as iopofosine or CLR 131) for the treatment of Waldenstrom macroglobulinemia (WM) patients;\n\n●our projected operating results, including research and development expenses;\n\n●our ability to continue developing iopofosine I 131;\n\n●whether the milestones and other conditions to the mandatory exercise of the milestone-based warrants will be satisfied;\n\n●our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise;\n\n●our ability to continue development plans for our clinical and preclinical assets;\n\n●our ability to continue development plans for our Phospholipid Drug Conjugates (PDC)™;\n\n●our ability to advance our technologies into product candidates;\n\n●our ability to maintain orphan drug designation in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing’s sarcoma and lymphoplasmacytic lymphoma/WM, and the expected benefits of orphan drug status;\n\n●any disruptions to our suppliers;\n\n●our current view regarding general economic and market conditions, including our competitive strengths;\n\n●uncertainty and economic instability resulting from conflicts, military actions, terrorist attacks, natural disasters, public health crises, including the occurrence of a contagious disease or illness, cyber-attacks and general instability;\n\n●the future impacts of legislative and regulatory developments in the United States on the pricing and reimbursement of our product candidates;\n\n3\n\n[Table of Contents](#TOC)\n\n●our ability to meet the continued listing standards of Nasdaq;\n\n●assumptions underlying any of the foregoing; and\n\n●any other statements that address events or developments that we intend or believe will or may occur in the future. \n\nIn some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should,” “could”, “would” or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Forward-looking statements also involve risks and uncertainties, many of which are beyond our control. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this quarterly report.\n\nYou should read this report completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this report is accurate as of the date hereof only. Because the risk factors referred to herein could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.\n\nThis quarterly report on Form 10-Q contains trademarks and service marks of Cellectar Biosciences, Inc. Unless otherwise provided in this quarterly report on Form 10-Q, trademarks identified by ™ are trademarks of Cellectar Biosciences, Inc. All other trademarks are the property of their respective owners.\n\n​\n\n4\n\n[Table of Contents](#TOC)\n\n**PART I. FINANCIAL INFORMATION**"}